Oncolytics Biotech Inc T.ONC

IRENE Study

[ENEMENEMYNEMO]

Looking for info on the IRENE Trial and another one in multiple myeloma which don't seem to be mentioned on ONC's website?

[Noteable]

IRENE is a Phase 2 investigator sponsored trial in TNBC involving pelareorep + (Incyte's) Retifanlimab (INCMGA00012), a humanized monoclonal antibody targeting programmed death protein-1 (PD-1) and a recorded primary completion date as January 30, 2024. https://classic.clinicaltrials.gov/ct2/show/NCT04445844

[Noteable]

The IRENE study was in late-stage metastatic breast cancer patients who had previously received 1-2 lines of chemotherapy.  ONCY has prudently decided to move towards the earlier treatment of breast cancer on the expected relapse of ADCs, like Enhertu, in their treatment of breast cancer.  

[ENEMENEMYNEMO]

Thanks,  Irene's a hideous name anyway ...do you know if they ever posted results.  There are several registered trials on ClinicalTrial.gov  that are done but no results posted.  WTF is there no accountability here? Shite tonne of money spent for nothin' it seems!

[Azzak34]

Why "buy back in" then? 

[ENEMENEMYNEMO]

Cus it's changing from the Crazy Train to the Gravy Train??

[Lesalpes29]

Clown.

[Noteable]

March 11, 2024 - While many widely available resources for breast cancer patients lump all cases of the disease together, Gilead Sciences is drilling down into the specifics of metastatic breast cancer (MBC) in particular.  The Expose MBCwebsite went live earlier this month—just in time for Triple-Negative Breast Cancer (TNBC) Awareness Day on March 3—and is a collaborative effort

[askretka]

Not really following Irene study at moment but best article I've seen on Multiple Myeloma front is in this article in February 2024. https://cancercenter.arizona.edu/news/2024/02/researchers-discover-innovative-new-treatment-approach-multiple-myeloma Cheers!!!!!!!!!!!!